Max Healthcare Institute Ltd (MAXHEALTH) Q1 FY27 Earnings Call: Medical Education Entry Approved, Sees 20,000-40,000 Bed Ceiling

Max Healthcare Institute Ltd held its Q1 FY27 earnings call on August 13, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Growth, Occupancy & Margin Performance

• Network revenue of Rs.2,982 crores — grew 16% YoY in Q1 FY 2026-2027, with operating EBITDA of Rs.704 crores (margin 24.8%).
• ARPOB of Rs.81,900 — up 5% YoY; average occupancy remained above 75% despite a 13% YoY increase in bed capacity.
• Occupied bed days rose 10% YoY — indicating healthy volume growth even as new beds were being commissioned during the quarter.
• International patient revenue of Rs.247 crores — accounted for 9% of hospital revenue and grew 18% YoY; digital revenue reached Rs.941 crores (~32% of total revenue).
• Oncology revenue share dropped to 22% — from 26% in Q1 FY 2025-2026, driven by the discontinuation of high-value chemotherapy drugs for institutional patients; excluding oncology, gross revenue grew 20% and ARPOB 9% YoY.

Brownfield Pipeline, Timelines & Project Updates

• Board approved Rs.425 crores capex — for a 200-bed brownfield tower at Vaishali, with expected commissioning before FY30 (ending March 2030).
• Max Smart (200 beds): 50% operationalised — in Q1 FY 2026-2027 running at ~80% occupancy; remaining 50% expected by end of Q2 FY 2026-2027. Management expects revenue ramp-up to begin in Q2/Q3 FY 2026-2027.
• Nanavati Max: phase 2 (271 beds) by FY30 — phase one (remaining 50 beds) nearing completion; current beds at ~80% occupancy with EBITDA approaching corporate average. Phase two requires shutdown of ~100 beds, timeline ~2.5 years (likely FY28-29).
• Sector 56 Gurgaon: 500 beds phased by end of FY27 — Bhubaneswar renovation (250 beds) within 12 months; Nagpur (100 beds) by FY28; Zirakpur (400 beds) by FY28; Pitampura (200 beds) by FY29; Patparganj (400 beds) by end of FY29; Pune (450 beds) by FY30.
• Regulatory approvals for Thane & Shaheed Path — expected in ~6 months (likely Q3/Q4 FY 2026-2027), with construction taking 30-36 months thereafter (estimated completion FY29-30 or FY30-31).
• Acquisitions at Lucknow, Noida, Nagpur — strong ramp-up in occupancy, revenues and profitability over 2-2.5 years since acquisition; company now moving toward brownfield capacity expansion at all three.

CGHS, Insurance Renegotiations & Oncology Recovery Path

• CGHS business is loss-making — management stated it "only contributes to fixed costs" and no approach to government for a rollback was mentioned. The super-specialty rate arrears began flowing from June, and the run rate aligns with the annual CGHS target of Rs.140 crores for FY 2026-2027.
• Oncology revenue expected to normalise by Q4 FY 2026-2027 — management expects growth to start leveling from Q3 FY 2026-2027, following the decision to stop supplying OAC drugs under the new CGHS MOA. Oncology is ~25%+ of revenue with the largest CGHS institutional share, particularly in Delhi.
• Institutional revenue share expected to continue declining — as a result of a "concerted effort," though management did not provide a specific target level. Institutional patient bed share declined in Q1 FY 2026-2027 vs the prior quarter.
• Insurance impanelment renegotiations ongoing — renewals with GIC and other insurers are due in September-October 2026. The previously agreed 6% automatic price revision from the last stalemate will take effect for those contracts. Engagement with IRDA and TPAs has produced a general agreement that price revisions should reflect hospital inflation, with a recommendation to be made to IRDA.
• Parliamentary Standing Committee report on healthcare affordability — management noted the sector "needs a viable and conducive investment environment" for building hospitals and expects "wise minds" to consider this balance; the company was not consulted by the committee.

For-Profit Medical College Entry, Research & Capital Allocation

• Board approved entry into medical education — following the government's draft notification allowing for-profit companies to open medical colleges (previously restricted to not-for-profits). Management cited "government's draft notification allowing for-profit companies to open medical colleges" as the catalyst.
• Capital requirement: ~Rs.300 crores per 150-bed college — (period unspecified for individual project). Management sees ROCE of over 25-30% for medical college operations, citing strong demand as less than 2% of NEET-qualifying students find seats.
• First campus planned at 27-acre Lucknow site — with potential expansion to other hospitals with large land parcels. The entity will be a 100% subsidiary of Max Healthcare Institute Limited. Management views this as backward integration, leveraging existing DNB training, faculty, and curriculum.
• PG courses in oncology specialty to begin — commercial operations expected over the next few years, funded entirely through internal accruals. Acquisitions are also possible to accelerate timelines.
• Max Research Center established — with a track record of 750+ clinical trials, 2,200+ investigator-initiated studies, and 3,500 published papers.

Working Capital Drag, Debt Capacity & Conversion Metrics

• Free cash flow of Rs.397 crores in Q1 FY27 — EBITDA grew 15% but operating free cash flow rose only 3% due to a Rs.250 crore accounts receivable build-up vs Q4 FY26, concentrated in CGHS and other PSU receivables linked to a new portal that temporarily delayed bill processing.
• DSO increased to 95 days — from 87 days in Q4 FY26; cash conversion rate slipped to 56% in Q1 FY 2026-2027, below the 62-65% range management targets. Management expects AR to normalise as collections from the new CGHS portal have resumed (full normalisation period unspecified).
• Net debt of Rs.2,384 crores (net debt/EBITDA below 1x) — management would be willing to increase leverage to 2.5x via acquisitions. Barring M&A, net debt is expected to marginally increase through FY 2026-2027 due to ongoing capex at Shaheed Path and other projects, but should be fully funded and debt paid down in 3-4 years.
• No material OPEX increase expected until Gurugram project — the sharp increase in Q1 FY 2026-2027 was driven by new capacities at Mohali, Nanavati, Smart, and Bhubaneswar. Staffing costs for new brownfield expansions (e.g., a 400-bed hospital starting with 20 beds) will rise in the near term, but break-even for brownfields is lower than greenfields.
• Clinician cost increase accounted for ~1% of cost structure — net revenue ~15%, direct cost ~16%. No significant impact from crude price increases on consumable prices; crude-related delays in materials (e.g., imported furniture) have largely been resolved.

Long-Term Capacity Ceilings, Bed Doubling & Growth Vectors

• Chairman sees 20,000-40,000 beds as realistic ceiling — Abhay Soi stated it is "not viable for top private hospital chains to reach 100,000 beds each over two decades" (by ~FY2046), as that would require building 300,000 beds total — more than India's current total private beds (~100,000). He expects the trend of doubling capacity every 4-5 years to continue.
• ARPOB growth of 7-8% expected over 15-20 years — management stated "ARPOB growth of 7–8%... is expected to persist over the next 15–20 years," driven by innovation in novel treatments rather than inflation alone.
• Kalinga hospital turnaround: 50-80% enhancement potential — over the next 12 months via renovations, technology upgrades, clinical programs, and building an additional 200-250 beds. Current occupancy is ~30%, ARPOB Rs.35,000.
• Medical education as backward integration — management sees primary benefit as securing a pipeline of resident and DNB doctors, though no bond obligates them to stay. No reassessment of expansion plans needed in light of the parliamentary committee report; management believes any policy will be rational and its efficiency will enable superior returns and potential consolidation opportunities.
• Regional disclosure discontinued — to avoid revealing single-hospital state data; management may consider an aggregate "others" category in Q2 FY 2026-2027, but no commitment was made.